In addition, tetracaine derivatives appear to work for all gain‐of‐function RyR2 variants, which represent the vast majority (>95%) of all known CPVT‐causing variants (>150 described to date). The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.